Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4197
Source ID: NCT02692716
Associated Drug: Semaglutide
Title: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Acronym: PIONEER 6
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT02692716/results
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: semaglutide|DRUG: placebo
Outcome Measures: Primary: Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke, Number of participants experiencing a first event of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period. | Secondary: Time From Randomisation to First Occurrence of an Expanded Composite Cardiovascular Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, UAP Requiring Hospitalisation or Hospitalisation for Heart Failure, Participants experiencing first occurrence of an expanded composite CV endpoint \[defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, UAP (unstable angina pectoris) requiring hospitalisation or heart failure requiring hospitalisation\] are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.|Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint, Participants experiencing an event onset for each individual component of the expanded composite cardiovascular outcomes (defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, unstable angina requiring hospitalisation or heart failure requiring hospitalisation) are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.|Time From Randomisation to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, Non-fatal Myocardial Infarction or Nonfatal Stroke, Participants experiencing first occurrence of a composite CV endpoint (defined as all-cause death, non-fatal myocardial infarction or nonfatal stroke) are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.|Time From Randomisation to First Occurrence of Fatal or Non-fatal Myocardial Infarction, Number of participants experiencing a first event of a fatal or non-fatal myocardial infarction are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.|Time From Randomisation to First Occurrence of Fatal or Non-fatal Stroke, Number of participants experiencing a first event of a fatal or non-fatal stroke are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.|Time From Randomisation to All-cause Death, Number of all-cause deaths in the study are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Maximum treatment duration is dependent on event rates and is expected to be no longer than 19 months + 5 weeks of follow-up period.|Time to First AE Leading to Permanent Trial Product Discontinuation, Number of participants who permanently discontinued trial product in ths study are presented. Results are based on the on-treatment observation period which starts at the date of first dose on trial product; ends on last date on trial product +38 days (ascertainment window)., Maximum treatment duration is dependent on event rates and is expected to be no longer than 19 months + 38 days of ascertainment window.|Number of Serious Adverse Events, Number of serious adverse events were recorded from week 0 to week 87 in the study. Results are based on the on-treatment observation period which started at the date of first dose on trial product and ended on last date on trial product +38 days (ascertainment window)., Maximum treatment duration is dependent on event rates and is expected to be no longer than 19 months + 38 days of ascertainment window.|Change in Eye Examination Category, Participants with eye examination findings, normal, abnormal non clinically significant (NCS) and abnormal clinically significant (CS) at baseline (week -3) and end of treatment visit (week 83) are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Week -3, End of treatment|Change in Pulse Rate, Change from baseline (week 0) in pulse rate measured at the end of treatment visit (week 83) is reported. Results are based on the on-treatment observation period which started at the date of first dose on trial product, ended on last date on trial product +38 days (ascertainment window)., Week 0, End of treatment|Change in Systolic and Diastolic Blood Pressure, Change from baseline (week 0) in systolic and diastolic blood pressure measured at the end of treatment visit (week 83) is reported. Results are based on the on-treatment observation period which started at the date of first dose on trial product, ended on last date on trial product +38 days (ascertainment window)., Week 0, End of treatment|Change in Glycosylated Haemoglobin (HbA1c), Change from baseline (week 0) in HbA1c measured at the end of treatment visit (week 83) is reported. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Week 0, End of treatment|Change in Body Weight, Change from baseline (week 0) in body weight measured at the end of treatment visit (week 83) is reported. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Week 0, End of treatment|Change in Total Cholesterol - Ratio to Baseline, Change from baseline (week 0) in total cholesterol (mmol/L) at the end of treatment (week 83) visit is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Week 0, End of treatment|Change in LDL-cholesterol - Ratio to Baseline, Change from baseline (week 0) in LDL cholesterol (mmol/L) at end of treatment visit (week 83) is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Week 0, End of treatment|Change in HDL-cholesterol - Ratio to Baseline, Change from baseline (week 0) in HDL cholesterol (mmol/L) at end of treatment visit (week 83) is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Week 0, End of treatment|Change in Triglycerides - Ratio to Baseline, Change from baseline (week 0) in triglycerides (mmol/L) at end of treatment visit (week 83) is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment., Week 0, End of treatment
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 3183
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2017-01-17
Completion Date: 2018-09-25
Results First Posted: 2020-02-27
Last Update Posted: 2022-07-20
Locations: Novo Nordisk Investigational Site, Little Rock, Arkansas, 72211, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, 72143, United States|Novo Nordisk Investigational Site, Concord, California, 94520, United States|Novo Nordisk Investigational Site, Huntington Beach, California, 92648, United States|Novo Nordisk Investigational Site, La Jolla, California, 92037, United States|Novo Nordisk Investigational Site, La Mesa, California, 91942, United States|Novo Nordisk Investigational Site, Lancaster, California, 93534, United States|Novo Nordisk Investigational Site, Monterey, California, 93940, United States|Novo Nordisk Investigational Site, San Diego, California, 92111, United States|Novo Nordisk Investigational Site, San Ramon, California, 94583, United States|Novo Nordisk Investigational Site, Ventura, California, 93003, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, 33433, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, 34652, United States|Novo Nordisk Investigational Site, Roswell, Georgia, 30076, United States|Novo Nordisk Investigational Site, Savannah, Georgia, 31406, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, 96814, United States|Novo Nordisk Investigational Site, Springfield, Illinois, 62702, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, 46254, United States|Novo Nordisk Investigational Site, Michigan City, Indiana, 46360, United States|Novo Nordisk Investigational Site, Muncie, Indiana, 47304, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, 51501, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, 40502, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, 40503, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, 40213, United States|Novo Nordisk Investigational Site, Monroe, Louisiana, 71203, United States|Novo Nordisk Investigational Site, Slidell, Louisiana, 70461-4231, United States|Novo Nordisk Investigational Site, Canton, Michigan, 48187, United States|Novo Nordisk Investigational Site, Troy, Michigan, 48098, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, 68114, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, 68198, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, 89128, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, 03063, United States|Novo Nordisk Investigational Site, Albany, New York, 12203, United States|Novo Nordisk Investigational Site, Albany, New York, 12206, United States|Novo Nordisk Investigational Site, North Massapequa, New York, 11758-1802, United States|Novo Nordisk Investigational Site, Westfield, New York, 14787, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, 28803, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, 27834, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, 28401, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, 58104, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, 44195, United States|Novo Nordisk Investigational Site, Columbus, Ohio, 43203, United States|Novo Nordisk Investigational Site, Maumee, Ohio, 43537, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, 15009, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, 19114, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, 29621, United States|Novo Nordisk Investigational Site, Moncks Corner, South Carolina, 29461, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, 29572, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, 29303, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, 37404, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, 37411, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, 37660, United States|Novo Nordisk Investigational Site, Knoxville, Tennessee, 37938, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, 37203, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, 37212, United States|Novo Nordisk Investigational Site, Arlington, Texas, 76012-4637, United States|Novo Nordisk Investigational Site, Austin, Texas, 78705, United States|Novo Nordisk Investigational Site, Austin, Texas, 78731, United States|Novo Nordisk Investigational Site, Austin, Texas, 78749, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75230, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75231, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75390-9302, United States|Novo Nordisk Investigational Site, Hurst, Texas, 76054, United States|Novo Nordisk Investigational Site, Midland, Texas, 79707, United States|Novo Nordisk Investigational Site, Round Rock, Texas, 78681, United States|Novo Nordisk Investigational Site, San Antonio, Texas, 78220, United States|Novo Nordisk Investigational Site, San Antonio, Texas, 78228-6205, United States|Novo Nordisk Investigational Site, Waco, Texas, 76710, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, 05403, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, 23510-2015, United States|Novo Nordisk Investigational Site, Winchester, Virginia, 22601-3834, United States|Novo Nordisk Investigational Site, Annaba, 23000, Algeria|Novo Nordisk Investigational Site, Oran, 31000, Algeria|Novo Nordisk Investigational Site, Setif, 19000, Algeria|Novo Nordisk Investigational Site, Tizi Ouzou, 16015, Algeria|Novo Nordisk Investigational Site, Buenos Aires, B1704ETD, Argentina|Novo Nordisk Investigational Site, Buenos Aires, C1428ART, Argentina|Novo Nordisk Investigational Site, Caba, C1120AAC, Argentina|Novo Nordisk Investigational Site, Caba, C1428ART, Argentina|Novo Nordisk Investigational Site, Caba, C1440AAD, Argentina|Novo Nordisk Investigational Site, Cordoba, 5000, Argentina|Novo Nordisk Investigational Site, Lanus Este, B1824KAJ, Argentina|Novo Nordisk Investigational Site, Curitiba, Parana, 80030-110, Brazil|Novo Nordisk Investigational Site, Mogi das Cruzes, Sao Paulo, 08780-090, Brazil|Novo Nordisk Investigational Site, São José dos Campos, Sao Paulo, 12243-280, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, 01228-200, Brazil|Novo Nordisk Investigational Site, Calgary, Alberta, T2V 4J2, Canada|Novo Nordisk Investigational Site, Edmonton, Alberta, T6H 2L4, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, L6T 0G1, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, L6Z 4N5, Canada|Novo Nordisk Investigational Site, Concord, Ontario, L4K 4M2, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M5G 2C4, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, H4A 3T2, Canada|Novo Nordisk Investigational Site, Aarhus N, 8200, Denmark|Novo Nordisk Investigational Site, Esbjerg, 6700, Denmark|Novo Nordisk Investigational Site, Hellerup, 2900, Denmark|Novo Nordisk Investigational Site, Hvidovre, 2650, Denmark|Novo Nordisk Investigational Site, Odense, 5000, Denmark|Novo Nordisk Investigational Site, Bochum, 44791, Germany|Novo Nordisk Investigational Site, Dresden, 01307, Germany|Novo Nordisk Investigational Site, Elsterwerda, 04910, Germany|Novo Nordisk Investigational Site, Essen, 45219, Germany|Novo Nordisk Investigational Site, Falkensee, 14612, Germany|Novo Nordisk Investigational Site, Hamburg, 22607, Germany|Novo Nordisk Investigational Site, Ludwigshafen, 67059, Germany|Novo Nordisk Investigational Site, Münster, 48145, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, 23758, Germany|Novo Nordisk Investigational Site, Oldenburg, 23758, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, 66780, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, 66386, Germany|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, 500034, India|Novo Nordisk Investigational Site, Hyderbad, Andhra Pradesh, 500 012, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, 380006, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, 380052, India|Novo Nordisk Investigational Site, Kochi, Kerala, 682041, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, 673017, India|Novo Nordisk Investigational Site, Thiruvananthapuram, Kerala, 695031, India|Novo Nordisk Investigational Site, Goa, Maharashtra, 403 202, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, 400008, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, 400012, India|Novo Nordisk Investigational Site, Pune, Maharashtra, 411001, India|Novo Nordisk Investigational Site, Pune, Maharashtra, 411004, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, 110029, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, 141008, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, 600086, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, 700054, India|Novo Nordisk Investigational Site, New Delhi, 110001, India|Novo Nordisk Investigational Site, New Delhi, 110017, India|Novo Nordisk Investigational Site, Pune, 411011, India|Novo Nordisk Investigational Site, Haifa, 35152, Israel|Novo Nordisk Investigational Site, Holon, 58100, Israel|Novo Nordisk Investigational Site, Jerusalem, 91120, Israel|Novo Nordisk Investigational Site, Nahariya, 22100, Israel|Novo Nordisk Investigational Site, Petah-Tikva, 49100, Israel|Novo Nordisk Investigational Site, Rishon Le Zion, 75650, Israel|Novo Nordisk Investigational Site, Tel Aviv, 6937947, Israel|Novo Nordisk Investigational Site, Tel-Aviv, 64239, Israel|Novo Nordisk Investigational Site, Bergamo, 24127, Italy|Novo Nordisk Investigational Site, Catanzaro, 88100, Italy|Novo Nordisk Investigational Site, Chieti, 66100, Italy|Novo Nordisk Investigational Site, Milano, 20132, Italy|Novo Nordisk Investigational Site, Palermo, 90127, Italy|Novo Nordisk Investigational Site, Roma, 00133, Italy|Novo Nordisk Investigational Site, Roma, 00161, Italy|Novo Nordisk Investigational Site, Ipoh, Perak, 30990, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, 16150, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, 15586, Malaysia|Novo Nordisk Investigational Site, Kota Samarahan, 94300, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, 50400, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, 59100, Malaysia|Novo Nordisk Investigational Site, Kuching, 93586, Malaysia|Novo Nordisk Investigational Site, Melaka, 75400, Malaysia|Novo Nordisk Investigational Site, Putrajaya, 62250, Malaysia|Novo Nordisk Investigational Site, Seremban, 70300, Malaysia|Novo Nordisk Investigational Site, Guadalajara, Jalisco, 44600, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, 44650, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, 44670, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, 64460, Mexico|Novo Nordisk Investigational Site, Merida, Yucatan, 97070, Mexico|Novo Nordisk Investigational Site, San Luis Potosi, 78200, Mexico|Novo Nordisk Investigational Site, Almere, 1311RL, Netherlands|Novo Nordisk Investigational Site, Amsterdam, 1066 EC, Netherlands|Novo Nordisk Investigational Site, Eindhoven, 5631 BM, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, 7909 AA, Netherlands|Novo Nordisk Investigational Site, Nijmegen, 6525 GA, Netherlands|Novo Nordisk Investigational Site, Krakow, 31-261, Poland|Novo Nordisk Investigational Site, Krakow, 31-271, Poland|Novo Nordisk Investigational Site, Lublin, 20-044, Poland|Novo Nordisk Investigational Site, Poznan, 60-589, Poland|Novo Nordisk Investigational Site, Warszawa, 01-192, Poland|Novo Nordisk Investigational Site, Oradea, Bihor, 410025, Romania|Novo Nordisk Investigational Site, Targu Mures, Mures, 540142, Romania|Novo Nordisk Investigational Site, Tirgu Mures, Mures, 540142, Romania|Novo Nordisk Investigational Site, Bucharest, 010507, Romania|Novo Nordisk Investigational Site, Bucharest, 010627, Romania|Novo Nordisk Investigational Site, Bucharest, 020359, Romania|Novo Nordisk Investigational Site, Bucharest, 020475, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Galati, 800098, Romania|Novo Nordisk Investigational Site, Bloemfontein, Free State, 9301, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, 1827, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, 2013, South Africa|Novo Nordisk Investigational Site, Lenasia, Gauteng, 1827, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, 0181, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, 4001, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, 4450, South Africa|Novo Nordisk Investigational Site, Middleburg, Mpumalanga, 1055, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, 7925, South Africa|Novo Nordisk Investigational Site, Alcala de Henares, 28805, Spain|Novo Nordisk Investigational Site, Badalona, 08916, Spain|Novo Nordisk Investigational Site, Fuenlabrada - Madrid, 28942, Spain|Novo Nordisk Investigational Site, Madrid, 28046, Spain|Novo Nordisk Investigational Site, Málaga, 29006, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, 07198, Spain|Novo Nordisk Investigational Site, Pontevedra, 36071, Spain|Novo Nordisk Investigational Site, Sevilla, 41003, Spain|Novo Nordisk Investigational Site, Sevilla, 41010, Spain|Novo Nordisk Investigational Site, Valencia, 46014, Spain|Novo Nordisk Investigational Site, Valencia, 46026, Spain|Novo Nordisk Investigational Site, Kaohsiung City, 833, Taiwan|Novo Nordisk Investigational Site, Taichung City, 407, Taiwan|Novo Nordisk Investigational Site, Tainan city, 710, Taiwan|Novo Nordisk Investigational Site, Taipei, 100, Taiwan|Novo Nordisk Investigational Site, Bangkok, 10330, Thailand|Novo Nordisk Investigational Site, Bangkok, 10400, Thailand|Novo Nordisk Investigational Site, Bangkok, 10700, Thailand|Novo Nordisk Investigational Site, Chiang Mai, 50200, Thailand|Novo Nordisk Investigational Site, Klong Luang, Pathumthani, 12120, Thailand|Novo Nordisk Investigational Site, Nakhon Ratchasima, 30000, Thailand|Novo Nordisk Investigational Site, Ankara, 06100, Turkey|Novo Nordisk Investigational Site, Ankara, 06500, Turkey|Novo Nordisk Investigational Site, Antalya, 07058, Turkey|Novo Nordisk Investigational Site, Aydin, 09010, Turkey|Novo Nordisk Investigational Site, Denizli, 20070, Turkey|Novo Nordisk Investigational Site, Gaziantep, 27070, Turkey|Novo Nordisk Investigational Site, Istanbul, 34371, Turkey|Novo Nordisk Investigational Site, Istanbul, 34760, Turkey|Novo Nordisk Investigational Site, Izmir, 35100, Turkey|Novo Nordisk Investigational Site, Izmir, 35340, Turkey|Novo Nordisk Investigational Site, Rize, 53020, Turkey|Novo Nordisk Investigational Site, Aberdeen, AB25 2ZD, United Kingdom|Novo Nordisk Investigational Site, Bristol, BS10 5NB, United Kingdom|Novo Nordisk Investigational Site, Dundee, DD1 9SY, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, EH4 2XU, United Kingdom|Novo Nordisk Investigational Site, Exeter, EX2 5DW, United Kingdom|Novo Nordisk Investigational Site, Guildford, GU2 7XX, United Kingdom|Novo Nordisk Investigational Site, Norfolk, NR4 7UQ, United Kingdom|Novo Nordisk Investigational Site, Swansea, SA2 8PP, United Kingdom|Novo Nordisk Investigational Site, Watford, WD18 0HB, United Kingdom
URL: https://clinicaltrials.gov/show/NCT02692716

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress